1 / 3
文档名称:

度洛西汀肠溶胶囊联合振源胶囊治疗躯体形式障碍疗效研究 姚素华.pdf

格式:pdf   大小:1,220KB   页数:3页
下载后只包含 1 个 PDF 格式的文档,没有任何的图纸或源代码,查看文件列表

如果您已付费下载过本站文档,您可以点这里二次下载

分享

预览

度洛西汀肠溶胶囊联合振源胶囊治疗躯体形式障碍疗效研究 姚素华.pdf

上传人:学习好资料 2022/6/13 文件大小:1.19 MB

下载得到文件列表

度洛西汀肠溶胶囊联合振源胶囊治疗躯体形式障碍疗效研究 姚素华.pdf

相关文档

文档介绍

文档介绍:临床医药实践 2022年 6月第31卷第 6期  · 314 ·
DOI:1nuously 6weeks is a course of treatment.Record the scores of the Symptom Self-Rating Scale(SCL-90),Hamilton
Depression Scale(HAMD),and Adverse Reaction Scale before enrollment,2weeks,4weeks,and 6weeks of treatment,
and count the complications and overall Clinical effect.Results:After 2weeks of treatment,4weeks of treatment,and 6
weeks of treatment,the SCL-90scores of the observation group were lower than those of the control group(P<0.05).After
2weeks of treatment,4weeks of treatment,and 6weeks of treatment,the HAMD scores of the observation group were
all Lower than the control group(P<0.05),the total proportion of nausea,vomiting,dizziness,headache,and fatigue in
the observation group was significantly lower than that in the control group (P<0.05),and the total effective rate in
the observation group was higher than that in the control group (P<0.05).Conclusion:For patients with somatoform
disorders,the use of duloxetine combined with Zhenyuan Capsules can effectively improve the clinical symptoms of the
patients,reduce the depression score,and have fewer adverse reactions and reliable clinical effects.
Key words duloxetine;Zhenyuan capsule;somatoform disorder
  躯体形式障碍是一类以各种躯体症状与心理因